In 144 adults with stage 2/3 ADPKD (enrolment stopped short of 180), 3 years of monthly lanreotide did not slow measured GFR decline vs placebo (difference −0.3 ml/min/1.73 m² per year, 95% CI −3.4 to 2.8). Hypoglycaemia: 11.1% vs 1.4%.
RCTn = 144
Joly et al. A three-year randomized, double-blind, placebo-controlled study of lanreotide in stage 2/3 autosomal dominant polycystic kidney disease